-
Pramac Yamaha replace Miller with Guevara for 2027 MotoGP season
-
New Zealand make three changes for second South Africa Test
-
Bouaddi needs time at Man City despite 100m euro fee, says Maresca
-
Stocktwits Expands CME Group Alliance with the Integration of Single Stock Futures Data
-
MEXC Launches SHEIN Subscription with $1M Quota as Inaugural IPO Express Event
-
'Mature' Colapinto extends contact with Alpine through 2027
-
Iran, Qatar hold Hormuz talks as US blockade chokes Iran oil imports
-
Atletico rule out any talks with Barcelona over Alvarez
-
Defiant Dinusha helps Sri Lanka draw second India Test
-
Tech stocks lifted by Nvidia as broader markets struggle
-
Pakistan bowl against England in rain-delayed second Test
-
Delap joins Nottingham Forest in club-record deal
-
Barcola move from PSG to Liverpool 'on track': source
-
ICC President Akane Warns U.S. Sanctions Threaten Court's Future
-
Swallowed by silt: Survivors recount Nepal flood horror
-
Delays in Cancer Radiotherapy and Surgery Target Times
-
Germany's Merz hosts 'frugal' leaders ahead of EU budget battle
-
Acrid stench, charred walls reveal devastation of Pakistan infant ward fire
-
Barca sign Croatia goalkeeper Livakovic
-
Norway holds its breath as King Harald's health deteriorates
-
Rain delays England's bid to put off-field incidents behind them
-
Germany reports record 15,800 heat-related deaths this summer
-
World record holder Sawe withdraws from Berlin Marathon
-
YouTuber Chris Sails Arrested for Allegedly Falsifying Emergency Report
-
Driven by faith, activists stand up to fellow Jews to protect Palestinians
-
Dinusha defiant as Sri Lanka lead by 170 in India Test
-
Therapy Culture Performance: How the Lindsay Clancy Trial Sparked a Trend of Viral Maternal Distress
-
Taiwan lawmakers approve $7.6 bn drone budget as China threat grows
-
Norway's King Harald, 89, in 'extremely serious' condition
-
TechCentral.ie Daily Briefing: Agentic AI Firm Doubles Headcount to 60
-
How a glacier collapse may have caused Nepal-Tibet disaster
-
KiiChain Integrates TRON to Expand 24/7 On-Chain FX and Stablecoin Payments
-
Harmovest Capital Strengthens Global Financial Services Through Technology and Compliance
-
Japan to survey animal cafes over hygiene, welfare concerns
-
Nvidia to buy AI platform Hugging Face for $12.9 bn: report
-
Desperate families search for missing after Nepal floods
-
Palace intrigue in Uganda as succession battle heats up
-
The missing in Nepal-Tibet flash floods
-
'Housing First' approach gets Swedish city's homeless off streets
-
Search for 1,300 missing after deadly Nepal-Tibet floods
-
Czech duo Muchova and Mensik win US Open mixed doubles title
-
Once a top export, prized Kashmir carpet fades
-
Japan's 'polka dot queen' artist Yayoi Kusama dies aged 97
-
Search for 1,000 missing after deadly Nepal-Tibet floods
-
Nepal-Tibet disaster: what we know
-
Park So-yeon first woman to play for eSports powerhouse South Korea
-
China deploys record number of ships around Taiwan as pressure grows
-
Yayoi Kusama: Japan's kaleidoscopic, troubled 'polka dot queen'
-
Ruthless Bayern target treble as rivals reboot on Bundesliga return
-
Euro champ Hunt 'on her toes' against world's best in Zurich 100m
ADM Tronics Reports Third Quarter of Fiscal Year 2026 Results
NORTHVALE, NJ / ACCESS Newswire / February 13, 2026 / ADM Tronics Unlimited, Inc. (OTCQB:ADMT), a technology-based developer and manufacturer of innovative technologies and products, announces results for its third fiscal quarter ended December 31, 2025 of Fiscal Year 2026.
The upward trend in revenues, as reported in the Company's previous quarterly reports, continues for this third fiscal quarter of fiscal year ended March 31, 2026. For the nine months ended December 31, 2025 revenues increased 9% and 7% for the three months ended December 31, 2025, as compared to the same periods last fiscal year. Research and development activity and expense are continuing on the Company's proprietary non-invasive musculoskeletal pain therapy medical device. When engineering development is completed, the Company intends to submit a 510(k) Pre-Market Notification to the FDA for clearance to market.
Revenues for the three months ended December 31, 2025 were $803,088 as compared to $749,510 for the three months ended December 31, 2025, an increase of 8%. Loss from operations for the three months ended December 31, 2025 was $84,441 as compared to loss of $89,269 for the same period last year.
Revenues for the nine months ended December 31, 2025 were $2,664,2611 as compared to $2,447,391 for the nine months ended December 31, 2024, an increase of 9%. Income from operations for the nine months ended December 31, 2025 was $27,346 as compared to income of $29,154 for the same period last year.
Complete financial results are available in the Company's Quarterly Report on Form 10Q for December 31, 2025, available at www.sec.gov.
Financial Highlights
Three Months Ended | Nine Months Ended | |||||||||||
December 31, | December 31, | |||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||
Net Revenues | $ | 803,088 | $ | 749,510 | $ | 2,664,261 | $ | 2,447,391 | ||||
Cost of Sales | $ | 530,592 | $ | 481,331 | $ | 1,534,675 | $ | 1,239,527 | ||||
Gross Profit | $ | 272,496 | $ | 268,179 | $ | 1,129,586 | $ | 1,207,864 | ||||
Total Operating Expenses | $ | 356,937 | $ | 357,448 | $ | 1,102,240 | $ | 1,178,710 | ||||
Income (loss) from operations | $ | (84,441 | ) | $ | (89,269 | ) | $ | 27,346 | $ | 29,154 | ||
Total other income (expense) | $ | (30,415 | ) | $ | (142,500 | ) | $ | 72,260 | $ | (45,850 | ) | |
Income (loss) before provision for income taxes | $ | (114,856 | ) | $ | (237,177 | ) | $ | 99,606 | $ | (16,696 | ) | |
Total provision (benefit) for income taxes | - | $ | 500 | $ | 1,500 | $ | 1,500 | |||||
Net income (loss) | $ | (114,856 | ) | $ | (237,677 | ) | $ | 98,106 | $ | (18,196 | ) | |
Basic and diluted per common share | $ | (0.00 | ) | $ | (0.00 | ) | $ | (0.00 | ) | $ | (0.00 | ) |
Weighted average shares of common stock outstanding - basic and diluted | 67,588,492 | 67,588,492 | 67,588,492 | 67,588,492 | ||||||||
About ADMT
ADMT is a diversified, technology-based developer and manufacturer of innovative technologies and products. Its core competency is its ability to conceptualize a technology, bring it through development, into manufacturing and commercialization, all in-house. ADMT has three areas of activity: Proprietary Electronic Medical Devices; Design, Engineering, Regulatory and Manufacturing Services; and, Eco-Friendly, Safe, Water-Based Formulations. The Company's headquarters, laboratories, FDA-Registered and ISO-13485 Certified medical device and manufacturing operations are located in Northvale, NJ. ADMT's multi-disciplinary team of engineers, researchers and technologists utilize advanced technology infrastructure, for the research, development and commercialization of diversified technologies. Additional information is available at admtronics.com
Sign up for ADMT Investor News Updates emails by filling in the form at the bottom of the page at this link: https://admtronics.com/investor-relations/
Except for historical information contained herein, the matters set forth in this news release are "forward-looking" statements (as defined in the Private Securities Litigation Reform Act of 1995), including statements regarding future revenue growth and performance. Although ADMT believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations. Factors that could contribute to such differences include those described from time to time in ADMT's filings with the SEC, news releases and other communications. The Company assumes no obligation to update the information contained in this news release.
Contact Information:
Andre DiMino
+12017676040
[email protected]
SOURCE: ADM Tronics Unlimited Inc.
View the original press release on ACCESS Newswire
W.Morales--AT